Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
15 October 2020
GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update
14 October 2020
GenSight Biologics Appoints Elsy Boglioli to its Board of Directors
28 September 2020
GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology
21 September 2020
GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)
15 September 2020
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
04 August 2020
GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital
30 July 2020
GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update
21 July 2020
GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation
09 July 2020
GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021
06 July 2020
GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment
View previous 9 articles
1
…
8
9
10
11
12
13
14
15
16
17
18
…
24
View next 9 articles
Go back to the page of the page